A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Clinical trial NCT04847050 · COMPLETED

Trial details

NCT number: NCT04847050
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumor Malignancy Hematologic Malignancy Leukemia Lymphoma Multiple Myeloma

Start date: 2021-04-28
Primary completion: 2023-05-25
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.